J Biol Chem (1999) 274:114558
[14] [15] No significant side effects have been noted at moderate dosages
They represent two distinct paths to mental optimization
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
GHK-Cu results: what to expect and when Realistic timelines matter
For studies that reported the number of individual side effects but not the number of patients experiencing a side effect, this probability was determined using maximum likelihood estimation under a binomial model
